---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-25-000245"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:02:03.706573+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q2 revenue $232.1M (+31% YoY); raises FY2025 guidance to $915-925M

## Summary
- Q2 total revenue $232.1M (+31% YoY); Oncology $158.7M (+22%), Screening $14.8M, Biopharma $56.0M (+28%).
- Non-GAAP gross margin 66% (vs 60% YoY); net loss $99.9M ($0.80) vs $102.6M ($0.84) YoY.
- 2025 revenue guidance raised to $915-925M (24-25% growth) from prior $880-890M; non-GAAP gross margin guidance 63-64%.
- Shield screening test volume expected 68,000-73,000; Screening revenue guidance raised to $55-60M.
- Free cash flow burn -$65.9M in Q2 vs -$99.1M; core business ex-Screening on track for FCF breakeven in Q4 2025.

## SEC filing metadata
- accession: 0001576280-25-000245
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628025000245/0001576280-25-000245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628025000245/gh-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-25-000245
- JSON: https://secwatch.observer/filing/0001576280-25-000245.json
- Plain text: https://secwatch.observer/filing/0001576280-25-000245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.